Centre for Ophthalmology and Visual Science, Lions Eye Institute, The University of Western Australia, Perth, Australia.
Ophthalmology. 2010 May;117(5):954-65. doi: 10.1016/j.ophtha.2009.10.026. Epub 2010 Feb 16.
To evaluate the effectiveness of a laser-induced chorioretinal venous anastomosis (L-CRA) as a treatment for nonischemic central retinal vein occlusion (CRVO).
Prospective, randomized, controlled, multicenter clinical trial.
A total of 113 consecutive patients with a nonischemic CRVO of >3 months' duration and visual acuity of < or =20/50.
Patients were randomized to L-CRA (58 patients) or conventional care (55 patients). They underwent standardized retinal photography, fluorescein angiography, and ophthalmic examinations, together with standardized assessments of best-corrected visual acuity, performed by masked visual acuity assessors using Early Treatment Diabetic Retinopathy Study protocols. Analysis was performed by intention-to-treat.
The primary outcome measure was change in visual acuity at 18 months. Secondary outcomes were progression of retinal ischemia and rates of adverse events.
A total of 53 control patients and 55 treatment patients completed the study. The 2 groups were comparable for age, age- and gender-adjusted mean visual acuity, and most other parameters. In the treated group of 55 patients, 42 (76.4%) developed an L-CRA. Over the 18-month follow-up period, treated eyes had an 8.3 letter mean improvement from baseline compared with control eyes (P = 0.03). Treated eyes that developed a functional L-CRA achieved an 11.7 letter mean improvement from baseline over the control group after 18 months (P = 0.004). Conversion to the ischemic CRVO category occurred in 20.8% of control eyes and in 9.6% of treated eyes overall (P = 0.33). Of the treated group who developed an L-CRA where the retinal ischemia was due to progression of the CRVO, 4.9% progressed to the ischemic category (P = 0.03). Neovascularization developed at the site of the L-CRA in 10 of 55 treated eyes (18.2%). Vitrectomy surgery was required by 5 of 55 treated eyes (9.1%) because of macular traction or nonresolving vitreous hemorrhage.
Chorioretinal venous anastomosis was created in 76.4% of eyes with nonischemic CRVO in this study. Eyes that developed an anastomosis had a significant improvement (11.7 letters) in final visual acuity after 18 months, compared with eyes in the control group (P = 0.004). Complications were managed successfully with careful follow-up and early intervention.
评估激光诱导脉络膜视网膜静脉吻合术(L-CRA)治疗非缺血性中央视网膜静脉阻塞(CRVO)的有效性。
前瞻性、随机、对照、多中心临床试验。
共纳入 113 例非缺血性 CRVO 病程>3 个月且视力<或=20/50 的连续患者。
患者随机分为 L-CRA(58 例)或常规治疗(55 例)组。他们接受标准化视网膜摄影、荧光素血管造影和眼科检查,并使用早期糖尿病视网膜病变研究方案由盲法视力评估员进行标准化最佳矫正视力评估。分析采用意向治疗。
主要结局测量指标为 18 个月时视力变化。次要结局为视网膜缺血进展和不良事件发生率。
共有 53 例对照组患者和 55 例治疗组患者完成了研究。2 组在年龄、年龄和性别调整后的平均视力以及大多数其他参数方面相似。在治疗组的 55 例患者中,42 例(76.4%)形成了 L-CRA。在 18 个月的随访期间,治疗眼与对照组相比,基线时平均视力提高了 8.3 个字母(P=0.03)。在 18 个月后,形成功能性 L-CRA 的治疗眼与对照组相比,平均视力提高了 11.7 个字母(P=0.004)。对照组中有 20.8%的眼转变为缺血性 CRVO 类别,治疗组中总体有 9.6%的眼转变为缺血性类别(P=0.33)。在因 CRVO 进展而导致视网膜缺血的治疗组中,有 4.9%的眼进展为缺血性类别(P=0.03)。55 例治疗眼中有 10 例(18.2%)在 L-CRA 部位发生新生血管化。由于黄斑牵引或未解决的玻璃体积血,有 5 例(9.1%)治疗眼需要玻璃体切除术。
在这项研究中,76.4%的非缺血性 CRVO 眼形成了脉络膜视网膜静脉吻合术。与对照组相比(P=0.004),形成吻合术的眼在 18 个月后最终视力有显著提高(11.7 个字母)。并发症通过仔细的随访和早期干预得到成功处理。